Arcus Biosciences, Inc. (RCUS)
NYSEHealth CareBiotechnologySnapshot 2026-09-04
$29.66-1.56%
Close 2026-09-04 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RCUS
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks RCUS against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Advance casdatifan across all lines of treatment in clear cell renal cell carcinoma, including first-line TKI-free regimens and combination therapies.
Stated as a priority in 3 of last 3 quarters. Arcus emphasizes establishing casdatifan as backbone therapy across all lines of ccRCC treatment, including first-line TKI-free regimens. Cash runway supports aggressive advancement with $1.0B at 2025-Q4 declining to $775M at 2026-Q2. Revenue showed decline from $33M in 2025-Q4 to $17M in 2026-Q1 but rose to $41M in 2026-Q2. The trajectory is delivering with ongoing clinical progress and financial resources aligned.
“Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for ccRCC.”
“Our highest priority is to establish casdatifan as a foundational standard of care in kidney cancer.”
“We are focused on rapidly enrolling PEAK-1 and determining the optimal TKI-free casdatifan-based regimen for a registrational trial in 1L ccRCC.”
Accelerate enrollment in PEAK-1 Phase 3 study and initiate first-line Phase 3 study by year-end 2026.
Stated in 3 of last 3 quarters. Management reports accelerating enrollment in PEAK-1 Phase 3 study with completion expected by year-end 2026 and plans to initiate a first-line Phase 3 study by the same time. Financials show stable cash runway supporting these milestones. The trajectory is delivering as enrollment progresses and study initiations are planned.
“Enrollment in PEAK-1 is accelerating and on track to complete by year-end 2026.”
Develop oral MRGPRX2 antagonist AB102 and other small-molecule candidates targeting TNF, CCR6, STAT6, CD89, and CD40L.
Stated in 2 of last 3 quarters. Arcus is advancing its immunology pipeline with AB102 expected to enter clinical trials in 3Q26 and other candidates progressing toward IND readiness by 2027-2028. Financials show continued investment in R&D supporting these programs. The trajectory is delivering with clear development milestones set.
“AB102 expected to initiate first-in-human study in 3Q26; multiple immunology candidates expected through 2028.”
Discontinue Phase 3 STAR-121 and STAR-221 studies and wind down related development activities.
Stated in 2 of last 3 quarters. Management has discontinued Phase 3 STAR-121 and is winding down STAR-221 and EDGE-Gastric studies following futility analyses. This is reflected in reduced R&D expenses related to these programs. The trajectory is delivering as planned wind-down proceeds.
“Discontinuation of Phase 3 STAR-121 study due to futility; winding down Phase 3 STAR-221 study.”
Manage cash, cash equivalents, and marketable securities to fund operations through at least the second half of 2028.
Stated in 4 of last 4 quarters. Arcus consistently reports cash runway sufficient to fund operations through at least the second half of 2028. Cash and equivalents declined from $1.0 billion at 2025-Q4 to $775 million at 2026-Q2 due to R&D spending. The trajectory is delivering with financial resources aligned to support ongoing development.
“Cash runway until at least the second half of 2028 with $775 million in cash and equivalents.”
Over the trailing year it converted 1.11x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
10 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“PEAK-1 enrollment is accelerating and initiation of a 1L Phase 3 study is expected by year-end 2026.”
“PEAK-1 started enrollment in 3Q25 and is now enrolling globally; Phase 3 1L study planned by end of 2026.”
“Selected AB102 as clinical candidate expected to enter clinic in 3Q26; advancing oral small-molecule TNF inhibitor.”
“Rapidly winding down activities related to Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies.”
“Cash runway until at least the second half of 2028 with $876 million in cash and equivalents.”
“Cash runway until at least the second half of 2028 with $1.0 billion in cash and equivalents.”
“Cash runway sufficient to fund operations until at least the second half of 2028.”